Patrick O’Donnell
President & CEO, NanoHive Medical
For over 25 years, Patrick O’Donnell has established a successful track record in the medical
device, orthobiologics, and biomaterials industries with technologies in the orthopedic, spine,
neurosurgery, sports medicine, interventional radiology markets.
As an executive officer and Board member of biosurgery and medical device companies, Mr.
O’Donnell has created the strategy, built and led executive management teams and the
commercial organizations, structured strategic alliances, and raised capital (over $100M) to
fund and execute the product development and clinical programs towards regulatory
milestones and a pathway to liquidity for shareholders.
Mr. O’Donnell currently serves as a member of the Board of Directors at NanoHive Medical
(Boston, MA, USA). Prior Board roles include; ChitogenX (Montreal, Canada), Histogenics
Inc, Proteothera, Inc., ProChon BioTech, and served as a Strategic Advisor to the Board of
Renovos Biologics (Southhampton, Hampshire, U.K).
Mr. O’Donnell currently serves as the Chairman, President & Chief Executive Officer of
NanoHive Medical, LLC, a 3D printing medical device company focused on the development
of bioactive, intelligent interbody fusion devices. At NanoHive, Mr. O’Donnell led the re-
start of NanoHive (formerly HD Lifesciences LLC) which included management of daily
operations. This entailed creation of a build-to-profitability strategy leveraging the distinct
intellectual property portfolio, raising $13M in capital to execute the strategy to exit, building
of new executive management team, and commercial execution to include establishment of an
independent/direct sales channel and parallel strategic distribution partners as well as securing
Market Access in the United States and select international markets.
Prior to NanoHive Medical, Mr. O’Donnell served as General Manager and Executive Vice-
President of North America for BoneSupport A.B. where he built and led the U.S. commercial
operations organization for the Swedish-based local delivery device and drug combination
product company in the orthopedic markets. During his tenure at BoneSupport, Mr.
O’Donnell established the U.S. organization where he developed the U.S. commercial
strategy and transitioned the commercial model from distribution partner Zimmer-Biomet to
an independent distribution channel of 50 distributors and 500 sales representatives. Mr.
O’Donnell built and managed the U.S. commercial operations and executive management
team.
Prior to BoneSupport, Mr. O’Donnell served as the Founder, Director, and Chief Executive
Officer of ProteoThera, Inc., an early-stage biotech company with matrix-binding protein
fusion technology for local delivery of small molecules and proteins to address articular joint
inflammatory diseases. Mr. O’Donnell is responsible for building the senior management
team, driving strategy, managing operations, and fund-raising including the closing of a
$4.1M convertible note of which the proceeds will capitalize the Company through GMP
production and toxicology towards first-in-human clinical research. Mr. O’Donnell lead the
organization to a research and licensing collaboration with Seikagaku, a Japan-based
orthobiologics company.
Prior to ProteoThera, Inc., Mr. O’Donnell served as President & CEO of Histogenics, Inc.,
Mr. O’Donnell was responsible for the organization’s daily operations, strategic direction,
management, cultivation of strategic partnerships, and funding. Mr. O’Donnell raised $61M
to capitalize Histogenics Corporation, proceeds of which led to a successful IPO and drove
the Company’s flagship NeoCartTM cartilage tissue-engineered implant through an FDA
Phase III clinical study.
Prior to Histogenics, Mr. O’Donnell served as the CEO of Prochon BioTech, an Israeli cell
therapy company focused on articular cartilage regeneration. At Prochon, Mr. O’Donnell
raised $13M, established a U.S based entity, built a senior management team, guided the
Company through an FDA Phase II clinical study, and merged the Company into Histogenics
Corporation in a stock-for-stock transaction.
Prior to Prochon BioTech, Mr. O’Donnell led the global marketing organization for
biomaterial start-up Confluent Surgical, Inc. While at Confluent, Mr. O’Donnell was
responsible for the global launch of the organization’s flagship hydrogel technology,
DuraSeal, into the neurosurgical market through an independent sales network. Mr.
O’Donnell was also responsible for building the technology’s value in the spine, thoracic, and
vascular markets. In 2007, Mr. O’Donnell played a participatory role in the $245M
acquisition and subsequent integration of Confluent Surgical by Tyco Healthcare.
Prior to Confluent Surgical, Mr. O’Donnell spent 13 years in sales, sales management, global
marketing, and strategic alliances in escalating positions of responsibility in the spine,
orthobiologics, and orthopaedics industry at Johnson & Johnson’s DePuy and DePuy Spine.
Mr. O’Donnell received his B.A. degree from the University of Wisconsin-Madison and
Master of Business Administration studies at Dominican University. Mr. O’Donnell and his
family live in Boston, Massachusetts.